Plainfield Health Care Center: Double Dementia Patch IN
PLAINFIELD, IN - A medication error investigation at Plainfield Health Care Center revealed significant safety violations after a resident with dementia was repeatedly found wearing two doses of a powerful dementia medication simultaneously, according to federal inspection records from February 2025.
Dangerous Medication Error Pattern Emerges
The most serious violation at Plainfield Health Care Center involved multiple instances of medication overdose with rivastigmine (Exalon) patches, a transdermal medication used to treat dementia symptoms. The resident, identified as Resident Q, was discovered on at least two separate occasions wearing two patches simultaneously - a potentially life-threatening medication error.
According to the inspection report, the first incident occurred on December 25, 2024, when the resident's wife arrived to take him home from the facility. She discovered he was wearing two Exalon patches on his body. When emergency room staff examined the resident upon his arrival at the hospital that day, they documented finding "two patches/doses of Rivastigmine on him" at 12:19 p.m.
The medication error pattern continued during the resident's second stay at the facility. On January 1, 2025, the resident's wife again discovered two rivastigmine patches on her husband during a visit. The inspection narrative notes that "the wife was upset because the resident had two patches of rivastigmine, one dated and one not dated."
The facility's response to these discoveries raised additional concerns. According to the resident's wife, when she reported the December incident, "the Administrator, Director of Nursing Services, and the nurse all told her it was not a medication error to have two Exalon patches on" - a statement that contradicts established medication safety protocols.
Medical Risks of Rivastigmine Overdose
Rivastigmine belongs to a class of medications called cholinesterase inhibitors, which work by preventing the breakdown of acetylcholine in the brain. When administered in excessive doses, these medications can cause severe and potentially fatal complications.
The manufacturer guidelines for rivastigmine patches specifically warn that "overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse, and convulsions." The guidelines further state that "increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved."
For residents with dementia, who may already have compromised communication abilities and underlying health conditions, medication overdoses pose particularly serious risks. The inability to clearly express symptoms of toxicity makes early detection challenging, potentially allowing dangerous side effects to progress unnoticed.
Proper medication administration protocols require that old patches be removed before applying new ones. The rivastigmine patches are designed to deliver medication continuously over 24 hours, making the removal of previous patches essential to prevent dangerous accumulation of the drug in the patient's system.
Facility Policy Failures and Documentation Issues
The inspection revealed significant gaps in the facility's medication administration protocols. While Plainfield Health Care Center had policies requiring staff to remove old patches before applying new ones, these protocols were not consistently followed or properly documented.
The facility's own policy, titled "Transdermal Drug Delivery System (Patch) Application," clearly states that staff should "observe site of previous application" and "if patches are continuous remove existing patch and cleanse site." The policy also requires documentation of the "site of administration to ensure rotation process."
However, interviews with facility staff revealed that documentation of patch locations was not standard practice. The Director of Nursing Services indicated that "neither order from both of his stays included documentation of where the patches had been applied, and it was not their policy to document where they apply medication patches."
This lack of documentation created conditions where multiple patches could be applied without staff awareness of existing medication. The Regional Nurse Consultant acknowledged that during the resident's first stay, medication orders included requirements for staff to sign off on patch removal, but during his second admission, "the order did not include the task that required staff to sign off that indicated to take the patch off."
The facility did complete medication error reports following the January 1 incident, documenting both a "transcription error" for failing to include patch removal documentation and an "other medication related error" for failing to remove the old patch when applying the new one.